Infant formula deals 'may' have broken Chinese anti-monopoly laws, Biostime admits
In the midst of an investigation into the pricing practices employed by it and other infant formula manufacturers in China, Biostime has admitted that the terms of its agreements with distributors “may” have broken anti-trust laws.